Biosimilars: Beginning a Conversation
Panelists: Christopher J. Campen,(1) PharmD, BCPS, BCOP (Moderator), Kelley D. Mayden,(2) MSN, FNP, AOCNP®, Ali McBride,(3) PharmD, BCPS, BCOP, and Michael Swit,(4) Esq.
(1) Greenville Health System, Greenville, South Carolina; (2) Wellmont Cancer Institute, Bristol, Virginia; (3) University of Arizona Cancer Center, Tucson; (4) Illumina, Inc.
Panelists' disclosures of potential conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2016;7;251–253 |
doi: 10.6004/jadpro.2016.7.3.1 |
© 2016 Harborside Press®
For access to the full length article, please sign in